How Is Myelofibrosis-Related Anemia Treated? Key Options

Anemia—a low hemoglobin level, often with too few or abnormal red blood cells—is a common and important complication of myelofibrosis. Treating it requires a tailored approach. Because no single treatment works for everyone, doctors first investigate the specific causes of your anemia before recommending a strategy ^[1]. Treatment options range from supportive care like blood transfusions to medications that stimulate red blood cell production, such as erythropoiesis-stimulating agents (ESAs), danazol, or specific targeted therapies like momelotinib ^[1][2]. In some cases, clinical trials may offer access to newer experimental drugs like luspatercept ^[1]. The goal of treatment is to reduce your symptoms, minimize your need for transfusions, and improve your overall quality of life.

Finding the Cause of Anemia

Before starting a specific treatment, your care team will evaluate your anemia to identify contributing factors. Anemia in myelofibrosis is often caused by progressive scarring in the bone marrow, an enlarged spleen that traps and destroys red blood cells prematurely, or high levels of hepcidin (a protein that prevents your body from properly using iron to make blood) ^[1].

However, doctors must also check for other common causes using a variety of tests, such as complete blood counts (CBC), a reticulocyte count, a peripheral blood smear, iron studies, vitamin B12 and folate levels, kidney function tests, and tests for hemolysis ^[3][4]:

• Bleeding or hemolysis: Hidden bleeding in the digestive tract or hemolysis (the premature breakdown and destruction of red blood cells).
• Nutritional deficiencies: Lack of iron, vitamin B12, or folate in your body. Important: Do not start iron supplements unless your doctor confirms an actual iron deficiency, because hepcidin-related iron restriction is not the same as true iron deficiency ^[4].
• Kidney disease: Your kidneys produce erythropoietin, a hormone needed to signal your bone marrow to make red blood cells. Poor kidney function can worsen anemia.
• Treatment-related anemia: Some common myelofibrosis medications, particularly the JAK inhibitor ruxolitinib, can suppress the bone marrow and cause or worsen anemia ^[1]. Never stop or change your JAK inhibitor without medical supervision.

Supportive Care with Transfusions

For patients with severe anemia or significant symptoms like extreme fatigue or shortness of breath, red blood cell transfusions provide immediate relief by quickly raising the blood count ^[5]. Transfusion decisions are highly individualized based on your hemoglobin levels, symptoms, cardiovascular disease, how quickly your counts are falling, and your doctor’s clinical judgment.

While transfusions are an important and necessary tool, relying on them long-term (transfusion dependence) can lead to iron overload, a condition where excess iron builds up and may damage organs like the liver or heart ^[6]. If you receive frequent transfusions, your doctor will monitor your iron levels using tests like serum ferritin. However, ferritin alone is an imperfect measure because inflammation and liver disease can also raise it ^[7][6]. If your doctor suspects significant iron overload, they may use other tests or imaging, and may discuss iron chelation therapy—medications to help your body safely remove excess iron ^[8]. Chelation is not automatic and depends on your ongoing transfusion burden, expected benefit, and potential medication side effects.

When to Seek Urgent Help

Seek immediate emergency medical care if you experience:

• Chest pain or pressure
• Severe or rapidly worsening shortness of breath
• Fainting, severe dizziness, or confusion
• Active bleeding
• Signs of a transfusion reaction (fever, chills, new rash, back pain, or dark urine during or shortly after a transfusion)

Medications to Stimulate Red Blood Cell Production

If your anemia requires ongoing management, your doctor may suggest medications to help your body make more of its own red blood cells:

• Erythropoiesis-Stimulating Agents (ESAs): These injectable drugs mimic the natural hormone that tells your bone marrow to make red blood cells ^[1]. Your doctor will check your serum erythropoietin (EPO) level; a lower EPO level (often defined as below 125 U/L or sometimes up to 500 mU/mL, which are equivalent measures depending on the lab) predicts a better chance of responding to the drug ^[9][10][11]. Being dependent on regular transfusions lowers the likelihood of response, but does not absolutely exclude you from trying ESAs ^[10]. ESAs carry a risk of thrombosis (blood clots) and can raise your blood pressure or push your hemoglobin too high ^[10]. Your doctor will monitor your blood pressure and counts closely, adjusting the dose as needed.
• Danazol: This synthetic hormone can help improve hemoglobin levels in some patients, though responses are sometimes infrequent or temporary ^[1]. Potential side effects include fluid retention, liver injury, lipid (cholesterol) abnormalities, and androgenic effects (such as acne, weight change, or hair and voice changes) ^[12]. Regular liver and health monitoring is required.
• Corticosteroids: Steroid medications like prednisone are sometimes used selectively to help manage anemia, often in combination with other drugs like danazol or other agents ^[1][13]. Because they are usually part of a combination regimen, the exact benefit of the steroid alone can be unclear ^[13]. Corticosteroids carry risks such as an increased risk of infection, high blood sugar, mood changes, and bone loss.

Targeted Therapies and Clinical Trials

If standard treatments are not effective, your doctor may consider targeted therapies or clinical trials:

• Momelotinib: This is a targeted JAK inhibitor specifically approved in many regions for appropriate adults with intermediate or high-risk myelofibrosis who also have anemia ^[2][14]. Unlike some other JAK inhibitors, momelotinib also blocks a protein called ACVR1, which helps lower hepcidin levels and improves your body’s ability to use iron for making red blood cells ^[14]. In clinical trials, it has been shown to improve anemia measures and reduce the need for transfusions compared to some older treatments ^[12]. Possible side effects include diarrhea, low platelets or other blood cells, liver toxicity, and a risk of infections ^[2].
• Luspatercept and Clinical Trials: Luspatercept is an injectable medication designed to help red blood cells mature in the bone marrow. It has shown promise in phase 2 clinical trials for some myelofibrosis patients with anemia, including those who are already taking ruxolitinib ^[15][1]. It is important to note that luspatercept is still investigational for myelofibrosis and is being studied in larger phase 3 trials (such as the INDEPENDENCE trial) ^[1]. It can cause side effects like high blood pressure, which requires monitoring ^[15]. You may be able to access it or other emerging treatments by participating in a clinical trial.

Setting Expectations and Monitoring

Managing anemia in myelofibrosis is an ongoing process and is only one part of your overall disease management. Worsening anemia may prompt your doctor to reassess your myelofibrosis and discuss broader disease-modifying strategies ^[16].

Responses to conventional treatments like ESAs, danazol, or corticosteroids can take months to become apparent, and the benefits may not be permanent ^[1]. Your care team will regularly monitor your blood counts, symptom relief, and any side effects to evaluate whether a medication is working ^[5]. If a treatment loses its effect, causes unacceptable side effects, or fails to improve your quality of life, your doctor may recommend adjusting the dose or switching to a different strategy ^[5].